Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$123.03
+0.3%
$108.81
$84.23
$157.98
$12.18B0.261.13 million shs1.02 million shs
Qiagen stock logo
QGEN
Qiagen
$44.36
+1.2%
$41.49
$37.63
$49.30
$9.86B0.671.15 million shs1.42 million shs
Repligen Co. stock logo
RGEN
Repligen
$121.18
-1.1%
$129.03
$102.97
$182.52
$6.81B1.21739,589 shs515,449 shs
Bio-Techne Co. stock logo
TECH
Bio-Techne
$47.93
-1.6%
$51.33
$46.01
$83.62
$7.51B1.461.31 million shs2.69 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
+0.32%+2.05%+15.56%+4.70%-12.42%
Qiagen stock logo
QGEN
Qiagen
+1.19%+5.01%+4.40%+15.60%+6.06%
Repligen Co. stock logo
RGEN
Repligen
-1.11%+0.81%-15.63%-22.59%-22.69%
Bio-Techne Co. stock logo
TECH
Bio-Techne
-1.56%+2.72%-4.62%-21.72%-39.63%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
4.975 of 5 stars
4.45.00.02.93.52.53.1
Qiagen stock logo
QGEN
Qiagen
3.2165 of 5 stars
1.22.01.74.52.81.71.3
Repligen Co. stock logo
RGEN
Repligen
4.9013 of 5 stars
4.32.00.04.54.03.31.9
Bio-Techne Co. stock logo
TECH
Bio-Techne
4.8986 of 5 stars
4.23.01.74.23.71.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
2.86
Moderate Buy$162.0031.68% Upside
Qiagen stock logo
QGEN
Qiagen
2.30
Hold$48.429.14% Upside
Repligen Co. stock logo
RGEN
Repligen
2.64
Moderate Buy$173.2542.97% Upside
Bio-Techne Co. stock logo
TECH
Bio-Techne
2.40
Hold$73.4453.23% Upside

Current Analyst Ratings Breakdown

Latest TECH, RGEN, QGEN, and NBIX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/9/2025
Bio-Techne Co. stock logo
TECH
Bio-Techne
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$95.00 ➝ $70.00
5/8/2025
Bio-Techne Co. stock logo
TECH
Bio-Techne
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$72.00 ➝ $63.00
5/8/2025
Bio-Techne Co. stock logo
TECH
Bio-Techne
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$75.00 ➝ $60.00
5/8/2025
Bio-Techne Co. stock logo
TECH
Bio-Techne
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$95.00 ➝ $75.00
5/6/2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
5/6/2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$137.00 ➝ $145.00
5/6/2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$160.00 ➝ $154.00
5/6/2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$137.00 ➝ $152.00
5/6/2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Perform ➝ Market Perform$96.00 ➝ $115.00
5/6/2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$155.00 ➝ $165.00
5/6/2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$138.00 ➝ $139.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$2.41B5.05$3.58 per share34.35$25.97 per share4.74
Qiagen stock logo
QGEN
Qiagen
$2.00B4.92$3.69 per share12.01$16.08 per share2.76
Repligen Co. stock logo
RGEN
Repligen
$650.43M10.47$2.26 per share53.61$35.19 per share3.44
Bio-Techne Co. stock logo
TECH
Bio-Techne
$1.21B6.22$1.69 per share28.30$13.15 per share3.64
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$341.30M$2.9537.4019.020.7714.49%13.38%9.73%8/7/2025 (Estimated)
Qiagen stock logo
QGEN
Qiagen
$83.59M$0.40123.5218.032.394.23%13.92%8.40%7/30/2025 (Estimated)
Repligen Co. stock logo
RGEN
Repligen
$35.60M-$0.45N/A51.354.54-4.64%4.21%2.94%7/29/2025 (Estimated)
Bio-Techne Co. stock logo
TECH
Bio-Techne
$168.10M$0.8248.4124.332.8813.22%12.73%9.75%8/6/2025 (Estimated)

Latest TECH, RGEN, QGEN, and NBIX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2025Q1 2025
Qiagen stock logo
QGEN
Qiagen
$0.50$0.55+$0.05$0.41$465.66 million$483.46 million
5/7/2025Q3 2025
Bio-Techne Co. stock logo
TECH
Bio-Techne
$0.51$0.56+$0.05$0.14$317.92 million$316.18 million
5/5/2025Q1 2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$0.70$0.08-$0.62$0.08$587.06 million$572.60 million
4/29/2025Q1 2025
Repligen Co. stock logo
RGEN
Repligen
$0.35$0.39+$0.04$0.10$163.65 million$169.17 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
N/AN/AN/AN/AN/A
Qiagen stock logo
QGEN
Qiagen
$0.250.56%N/A62.50%N/A
Repligen Co. stock logo
RGEN
Repligen
N/AN/AN/AN/AN/A
Bio-Techne Co. stock logo
TECH
Bio-Techne
$0.320.67%N/A39.02%N/A

Latest TECH, RGEN, QGEN, and NBIX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/19/2025
Bio-Techne Co. stock logo
TECH
Bio-Techne
quarterly$0.080.67%5/19/20255/19/20255/30/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
N/A
3.40
3.28
Qiagen stock logo
QGEN
Qiagen
0.38
3.61
3.09
Repligen Co. stock logo
RGEN
Repligen
0.26
10.44
8.76
Bio-Techne Co. stock logo
TECH
Bio-Techne
0.14
3.94
2.77

Institutional Ownership

CompanyInstitutional Ownership
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
92.59%
Qiagen stock logo
QGEN
Qiagen
70.00%
Repligen Co. stock logo
RGEN
Repligen
97.64%
Bio-Techne Co. stock logo
TECH
Bio-Techne
98.95%

Insider Ownership

CompanyInsider Ownership
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
4.80%
Qiagen stock logo
QGEN
Qiagen
9.00%
Repligen Co. stock logo
RGEN
Repligen
1.20%
Bio-Techne Co. stock logo
TECH
Bio-Techne
3.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
1,20098.97 million95.42 millionOptionable
Qiagen stock logo
QGEN
Qiagen
6,030222.29 million201.89 millionOptionable
Repligen Co. stock logo
RGEN
Repligen
2,02056.18 million55.36 millionOptionable
Bio-Techne Co. stock logo
TECH
Bio-Techne
3,000156.77 million151.92 millionOptionable

Recent News About These Companies

Brokerages Set Bio-Techne Co. (NASDAQ:TECH) Price Target at $73.44

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Neurocrine Biosciences stock logo

Neurocrine Biosciences NASDAQ:NBIX

$123.03 +0.39 (+0.32%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$123.03 0.00 (0.00%)
As of 04:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Qiagen stock logo

Qiagen NYSE:QGEN

$44.36 +0.51 (+1.16%)
Closing price 05/28/2025 03:59 PM Eastern
Extended Trading
$44.84 +0.48 (+1.08%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Repligen stock logo

Repligen NASDAQ:RGEN

$121.18 -1.36 (-1.11%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$121.06 -0.12 (-0.10%)
As of 05/28/2025 04:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Bio-Techne stock logo

Bio-Techne NASDAQ:TECH

$47.93 -0.76 (-1.56%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$48.60 +0.67 (+1.40%)
As of 05/28/2025 07:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.